Darolutamide - Isotope Labelled Standards
References
FAQ's
References
- Wohlfahrt, Gerd; Tormakangas, Olli; Salo, Harri; Hoglung, Lisa; Karjalainen, Arja; Knuuttila, Pia; Holm, Patrick; Rasku, Sirpa; Vesalainen, Anniina, Androgen Receptor Modulating Compounds, Orion Corporation, Finland, EP2493858B1, July 2, 2014
- Nawle, Yogita; Daroi, Pratibha; Sonawane, Bhushan; Bandre, Aditi; Munipalli, Vijaya Kumar; Warde, S. U.; Singh, Raman Mohan, Development, validation of HPTLC method for darolutamide in tablet dosage form, World Journal of Pharmaceutical Research, Volume: 11, Issue: 6Spec.Iss.,Pages: 868-881, 2022
Frequently Asked Questions
How are Darolutamide impurities controlled?
Impurities in Darolutamide are controlled by using appropriate manufacturing processes, quality control procedures, and analytical methods to detect and quantify impurities.
What is the impact of impurities on the pharmacokinetics of Darolutamide?
Impurities can affect the pharmacokinetics of Darolutamide, as they can alter the drug's absorption, distribution, metabolism, and excretion in the body.
Which solvent helps in the analysis of Darolutamide impurities?
Methanol is a solvent used in analyzing many impurities in Darolutamide.
What are the temperature conditions required to store Darolutamide impurities?
Darolutamide impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.